therapy-induced tumour secretomes promote resistance tumour progression 
drug resistance invariably limits clinical efficacy targeted therapy kinase inhibitors cancer12 show targeted therapy braf alk egfr kinase inhibitors induces complex network secreted signals drug-stressed human mouse melanoma human lung adenocarcinoma cells therapy-induced secretome stimulates outgrowth dissemination metastasis drug-resistant cancer cell clones supports survival drug-sensitive cancer cells contributing incomplete tumour regression tumour-promoting secretome melanoma cells treated kinase inhibitor vemurafenib driven down-regulation transcription factor fra1 situ transcriptome analysis drug-resistant melanoma cells responding regressing tumour microenvironment revealed hyperactivation several signalling pathways prominently akt pathway dual inhibition raf pi3 k/akt/mtor intracellular signalling pathways blunted outgrowth drug-resistant cell population braf mutant human melanoma suggesting combination therapy strategy tumour relapse thus therapeutic inhibition oncogenic drivers induces vast secretome changes drug-sensitive cancer cells paradoxically establishing tumour microenvironment supports expansion drug-resistant clones susceptible combination therapy 
